Trending...
- Inkdnylon Simplifies Digitizing and Vector Art Nationwide With Clear Pricing and Guided File Support
- Sleep Basil Launches Revamped Diamond Mattress Collection Page, Highlighting Performance, Craftsmanship, and Personalized Comfort
- Good Vibes Club and Instant IP Forge Strategic Partnership to Secure IP Brand Value in a Booming Digital Economy
CHENGDU, China, April 24, 2025 ~ Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) has announced that it will be showcasing the results of six clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3. These studies, led by Kelun, include data from their TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031).
The abstracts for these studies will be published on ASCO's official website on May 22, 2025, local time. The selected studies for ASCO 2025 are focused on various types of cancer and aim to present promising treatment options for patients.
One of the studies, titled "Sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study," will be presented as an oral presentation on June 1st. This study focuses on the use of sac-TMT as a potential treatment option for patients with advanced NSCLC.
More on illi News
Another study, titled "Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study," will also be presented as an oral presentation on May 31st. This study looks at the effectiveness of tagitanlimab in combination with other treatments for patients with recurrent or metastatic nasopharyngeal carcinoma.
The Phase II OptiTROP-Breast05 study will also be presented as a rapid oral presentation on May 30th. This study focuses on the use of sac-TMT as a first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC).
In addition to these presentations, there will also be a poster presentation on May 31st for the study titled "Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study." This study looks at the potential of combining sac-TMT and tagitanlimab as a first-line treatment option for patients with advanced NSCLC.
More on illi News
The remaining two studies, "Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study" and "Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer," will both be presented as poster presentations on May 31st and June 2nd respectively.
These studies demonstrate Kelun's commitment to developing innovative treatments for various types of cancer. The results presented at ASCO 2025 have the potential to significantly impact the lives of patients and improve their outcomes. The company looks forward to sharing their findings with the medical community at this prestigious event.
The abstracts for these studies will be published on ASCO's official website on May 22, 2025, local time. The selected studies for ASCO 2025 are focused on various types of cancer and aim to present promising treatment options for patients.
One of the studies, titled "Sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study," will be presented as an oral presentation on June 1st. This study focuses on the use of sac-TMT as a potential treatment option for patients with advanced NSCLC.
More on illi News
- Costa Oil Named Primary Sponsor of Carson Ware for the United Rentals 300 at Daytona International Speedway
- HBMHCW Expande Infraestructura de Cumplimiento para Argentina mientras América Latina Supera $1.5 Billones en Volumen Cripto
- Norisia Launches AI Formulated Luxury Multivitamin to Transform Daily Wellness in the UK
- Free Solar Installation Training Program Opens Pathways to Renewable Energy Careers in Englewood
- City Of Chicago Unveils First Video Animation of The New Concourse D at O'Hare International Airport
Another study, titled "Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study," will also be presented as an oral presentation on May 31st. This study looks at the effectiveness of tagitanlimab in combination with other treatments for patients with recurrent or metastatic nasopharyngeal carcinoma.
The Phase II OptiTROP-Breast05 study will also be presented as a rapid oral presentation on May 30th. This study focuses on the use of sac-TMT as a first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC).
In addition to these presentations, there will also be a poster presentation on May 31st for the study titled "Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study." This study looks at the potential of combining sac-TMT and tagitanlimab as a first-line treatment option for patients with advanced NSCLC.
More on illi News
- Liquatite® Flexible Conduit Powering Data Centers
- Jacob Emrani's Annual "Supper Bowl" Expected To Donate Thousands Of Meals
- NASA / Glenn Research Center Collaboration to Help Meet Rising Demand for Space Energy Beaming Tech / CIGS PV Modules from Ascent Solar: NAS DAQ: ASTI
- When Interpretation Becomes Conversation: Rethinking Engagement in the Museum Age
- Behind the Scenes: Licensing the Holiday Hideables Concept
The remaining two studies, "Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study" and "Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer," will both be presented as poster presentations on May 31st and June 2nd respectively.
These studies demonstrate Kelun's commitment to developing innovative treatments for various types of cancer. The results presented at ASCO 2025 have the potential to significantly impact the lives of patients and improve their outcomes. The company looks forward to sharing their findings with the medical community at this prestigious event.
Filed Under: Business
0 Comments
Latest on illi News
- STLE Partners with MPMA for the 2026 MPMA Fall Technical Meeting
- Market Value Enhancement From 2 Important New US Patents Issued for Strengthening Hair Enzyme Booster Technology to Caring Brands (NAS DAQ: CABR)
- Dr. Billy Laun Will Be Attending An Advanced Airway Management Course by AIME
- HELM Audio™ Partners with PQCrypto to Future-Proof Children's Hearing and Safety Data Using Post-Quantum Cryptography
- Wala Blegay to Announce Run for Congress in Maryland's 5th District on Feb. 4
- Luxury Lake-View Home Launches in Kissimmee's Bellalago community, Offering Privacy, Space, and Florida Resort-Style Living
- Sleep Basil Launches Revamped Diamond Mattress Collection Page, Highlighting Performance, Craftsmanship, and Personalized Comfort
- Sleep Basil Curates a Clearer Brooklyn Bedding Experience for Performance-Minded Denver Sleepers
- Naperville: North Central College Student Charged with Possession of Loaded Gun on Campus
- Nevada Man Launches Nationwide Animal Abuse Registry
- Star-powered Kappa Takeover Weekend Returns to the DMV June 18- 21, 2026, Hosted By Comedian Joe Clair W/ Dj Quick Silva (the Party Kingpin)
- Vault Innovation Group Sponsors AI Action Lab Chicago
- Scoop Social Co. Wins The Knot and WeddingWire Awards as Brand Expands Nationwide
- Chicago-Based Creator Launches Historically Accurate True-Crime Apparel on Kickstarter
- Denise Murphy Lenci Promoted to Century Fasteners Corp. – General Manager, Northeast Sales
- Chicago: Mayor Brandon Johnson, Department of Streets and Sanitation Reveal 25 Finalists for City's Fourth Annual 'You Name A Snowplow' Contest
- TiNY Puts Real Pets on the Payroll for New PetArmor Campaign
- P‑Wave Classics Launches Definitive New Edition of Hannah Webster Foster's The Coquette
- Strategic Expansion with 3 New Alliances — Jefferson Beach Yacht Sales, CFR YS & flyExclusive Incentive Partnership: Off The Hook YS: (N Y S E: OTH)
- Super League (N A S D A Q: SLE) Advances AI-Driven Playable Media with AdArcade, Solsten, and Meta-Stadiums Partnerships, Plus Roblox Theatre Launch